author-photo

Alvin F. Wong

Onyx Pharmaceuticals

45

Papers

2118

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Banoxantrone (AQ4N), tissue CYP 450 targeted prodrug: The results of a phase I study using an accelerated dose escalation

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

2016 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (20)
Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety

2013 Leukemia
Show All
- Source
- Cite
- Save
Citations (124)
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

2013 Drug Metabolism and Disposition
Show All
- Source
- Cite
- Save
Citations (103)
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

2012 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (115)
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

2012 Blood
Show All
- Source
- Cite
- Save
Citations (535)
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

2012 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (108)
Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

2011 Blood
Show All
- Source
- Cite
- Save
Citations (7)